Exabis Library
Welcome to the e-CCO Library!
P391: Are cut-off ranges of Infliximab serum levels in Crohn’s disease always the same in clinical practice?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P391: Differential use of vedolizumab in ulcerative colitis and Crohn's disease. Real life results from 2 tertiary referral centres in the United Kingdom
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P391: Gender differences in adalimumab continuation rates: Results of a Crohn’s disease cohort
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P391: Relative association of bowel urgency clinically meaningful improvement or bowel urgency remission versus stool frequency remission and rectal bleeding remission with improvement in Inflammatory Bowel Disease Questionnaire scores in patients with moderately-to-severely active Ulcerative Colitis: An analysis from LUCENT-1 and LUCENT-2 phase 3 clinical trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P391: The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn’s disease but not in ulcerative colitis. A nationwide study from the Eneida registry
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P391: Unpacking the different popular diets for pediatric Crohn's disease - concerns around nutritional adequacy
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P392 Initial experience with fibrin glue combined with infliximab treatment of postoperative anastomotic fistula in patients with Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P392: A mobile application to monitor Inflammatory Bowel Disease patients during intravenous biologic treatment: Results of a feasibility study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P392: Body mass index has no effect on treatment response in Crohn's disease patients with moderate disease activity who receive adalimumab
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P392: Comparing the accuracy and ease of use of self-administered ‘Malnutrition Universal Screening Tool’ (MUST) to screening by a health care professional using MUST to explore malnutrition rates in an outpatient inflammatory bowel disease clinic
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P392: Comparison of dietary nutrient and food additive intake between patients with moderately active ulcerative colitis, healthy stool donors and the general Australian population
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P392: Comprehensive video capsule endoscopy-based monitoring predicts short and long-term risk of disease flares in small bowel Crohn’s disease: A prospective cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P392: Risk factors for postoperative recurrence after ileocolic resection for Crohn's Disease: long-term results from a population-based cohort.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P392: To study the prevalence of depression and anxiety in patients of Inflammatory Bowel Disease (IBD) and the efficacy of psychopharmacotherapy in these patients: A pilot study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P393 Patient and physician perspectives on the management of inflammatory bowel disease: Role of steroids in the context of biologic therapy
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P393: Effect of filgotinib on anaemia in patients with Ulcerative Colitis in SELECTION
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P393: Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for acute severe colitis.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P393: Evaluation of pharmacokinetic profiles of SB2 as a biosimilar of reference infliximab
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P393: Investigation of Crohn’s disease patients receiving anti-TNF α therapy after surgery for intestinal stenosis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P393: Long-term prediction of infliximab response using CD-62L shedding assay: Longitudinal data from 5-year study in inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM